The Body Covers: The 6th Conference on Retroviruses and Opportunistic Infections
Abstract No. 398: Treatment with d4T + ddI + Nelfinavir + Hydroxyurea for Early or Recent Primary HIV Infection
February 2, 1999
Researchers from UCSF presented data from a study designed to assess the efficacy of a four-drug combination -- ddI/d4T/nelfinavir/hydroxyurea -- for patients with "early" HIV infection (defined as asymptomatic patients with a T-cell, or CD4, count above 500) or for recent HIV seroconverters (people who had been infected within 120 days of study entry).Abstract: Treatment with d4T + ddI + Nelfinavir + Hydroxyurea for Early or Recent Primary HIV Infection
Twenty patients with early HIV infection and sixteen patients with primary HIV infection were enrolled. All received the prescribed doses of d4T/ddI/nelfinavir, and took 500 mg of hydroxyurea twice-a-day. Baseline T-cell counts and viral loads were 745 cells and 10,300 copies/ml for those with early HIV infection, and 483 cells and 162,000 copies/ml for those with recent primary HIV infection. After 8 weeks of treatment, T-cell counts were 657 and 497 respectively, thus showing no statistically significant change. However, the CD4 cell percentage did increase from 33.8% to 39% in the early group, and from 26.3% to 37.4% in the seroconverter group. Ninety-five percent of subjects with early infection and 88% of those with recent primary infection had undetectable viral loads (below 50 copies). The study authors concluded that the four drug regimen was well-tolerated, and was a viable option for recently infected patients.
Authored by: J. Kahn, R. Cone, F. Hecht, H. Sax, M. Chesney, B. Herndier, L. Reynolds, J.M. Ledeine, L. Dunkle, and M. Flepp
This article was provided by The Body PRO. Copyright © Body Health Resources Corporation. All rights reserved.